Senesco Technologies Initiates Preclinical Studies For Cancer Target

Armen Hareyan's picture
Advertisement

Senesco Technologies has initiated preclinical lab studies at Mayo Clinic focused on multiple myeloma.

Advertisement

These studies will further test the ability of Senesco's Factor 5A gene technology to up-regulate apoptosis of cancer cells. Additionally, the studies will evaluate delivery molecules for encapsulation of Factor 5A to enhance the time the gene will circulate in the bloodstream before clearance by the body.

The data gathered from these animal experiments, together with the results of other Factor 5A studies, will be reviewed to determine its sufficiency for submission of a protocol to Mayo Clinic for human studies and to the Food and Drug Administration for an Investigational New Drug Application.

Previously, Senesco has announced the results of experiments performed at Mayo Clinic on a human multiple myeloma cell line. In those experiments, treatment with Factor 5A caused significant increase in apoptosis of the cancer cells compared to the untreated cells.

Advertisement